successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration成功与矩阵metalloproteinase-derived肽免疫治疗佐剂关节炎取决于肽的时间管理.pdf

Available online /4/4/R2 Research article Successful immunotherapy with matrix metalloproteinase- derived peptides in adjuvant arthritis depends on the timing of peptide administration Jolanda HM van Bilsen, Josée PA Wagenaar-Hilbers, Maarten JF van der Cammen, Mariska EA van Dijk, Willem van Eden and Marca HM Wauben Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, The Netherlands Corresponding author: Marca HM Wauben (e-mail: m.wauben@vet.uu.nl) Received: 20 November 2001 Revisions received: 13 March 2002 Accepted: 10 April 2002 Published: 7 May 2002 Arthritis Res 2002, 4:R2 © 2002 van Bilsen et al., licensee BioMed Central Ltd (Print ISSN 1465-9905; Online ISSN 1465-9913) Abstract We have recently found that matrix metalloproteinases peptide prior to AA induction reduced the arthritic symptoms. (MMPs) are targets for T-cell and B-cell reactivity in In contrast, administration of the MMP-10 peptide after AA experimental arthritis. In the present article, we investigate induction aggravated the arthritic symptoms. The present whether modulation of MMP-specific T-cell responses could study shows the possible usefulness of MMP peptides for influence the course of adjuvant arthritis (AA). Lewis rats were immunotherapy. However, a clear understanding of proper treated nasally with MMP peptides prior to or after AA timing of peptide administration is crucial for the development induction. Administration of the MMP-10 or the MMP-16 of such therapies. Keywords: adjuvant arthritis, immunotherapy, matrix metalloproteinase, nasal treatment, peptides Introduction